|
07 Dec 2020 |
ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting
|
|
06 Dec 2020 |
Bioniz Announces Positive Clinical Data of BNZ-1, First Anti-Cytokine Therapy to Demonstrate Efficacy in Treating Refractory Cutaneous T-Cell Lymphoma
|
|
06 Dec 2020 |
FDA approves Saxenda® for the treatment of obesity in adolescents aged 12–17
|
|
04 Dec 2020 |
Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management
|
|
04 Dec 2020 |
APEIRON Biologics: Patient recruitment completed in Phase II COVID-19 Clinical Trial of APN01
|
|
02 Dec 2020 |
Amicus Therapeutics Initiates Rolling Biologic License Application to the U.S. Food and Drug Administration for AT-GAA in Late-Onset Pompe Disease
|
|
28 Nov 2020 |
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency
|
|
23 Nov 2020 |
ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing
|
|
23 Nov 2020 |
Molecular Partners Doses First Cohort in Phase 1 Trial of COVID-19 DARPin® Therapeutic Candidate MP0420
|
|
18 Nov 2020 |
FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease
|
|
17 Nov 2020 |
Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)
|
|
17 Nov 2020 |
Once-weekly semaglutide 2.0 mg demonstrates superior reduction in HbA1c vs once-weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial
|
|
17 Nov 2020 |
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH
|
|
16 Nov 2020 |
Genenta’s Temferon™: Evidence of Controlled and Targeted Interferon Expression in Preliminary Phase I/II Clinical Data in Glioblastoma Multiforme
|
|
16 Nov 2020 |
Gilead and Novo Nordisk present new data from proof-of-concept trial in NASH
|
|
15 Nov 2020 |
Data from SG016 Phase II Clinical Trial published in Lancet Respiratory Medicine
|
|
13 Nov 2020 |
Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Study
|
|
13 Nov 2020 |
Axcella Presents Data for AXA1125 at The Liver Meeting® 2020
|
|
13 Nov 2020 |
AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury
|
|
13 Nov 2020 |
Xilio Therapeutics Presents Promising Preclinical Tumor-Selective Efficacy and Safety Data for XTX201 (IL-2) and XTX101 (anti-CTLA-4) at SITC
|
|
12 Nov 2020 |
amcure and Hinova Pharmaceuticals enter into an exclusive license agreement for the development, manufacturing and commercialization of AMC303 in oncology in the Greater China region
|
|
11 Nov 2020 |
SOTIO Presents Interim Data from its Phase 1/1b Study of SO-C101 in Patients with Advanced Solid Tumors at SITC 2020
|
|
10 Nov 2020 |
Medikine to Present Breakthrough Discoveries of Peptide-Based Agonists of IL-7 and IL-2/15 Receptors at SITC 2020
|
|
10 Nov 2020 |
Revance Announces Results of Phase 2 Trial of DaxibotulinumtoxinA for Injection in Plantar Fasciitis
|
|
09 Nov 2020 |
OncoNano Announces Positive Preclinical Data for ONM-400 Tumor Specific IL-2 Delivery at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
|
